Sun Pharmaceutical Industries announced two poster presentations at the ObesityWeek 2025 Scientific Sessions held from November 4-7, 2025, in Atlanta, USA.

In one of the posters, data from a subgroup of Phase 1b/2a Study of Utreglutide (GL0034) in overweight and obese individuals and Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in a phase 1b/2a study was presented. The subgroup comprised individuals with Class III Obesity and MASLD. Thirteen weeks of Utreglutide dosing in individuals with obesity and MASLD showed body weight and waist circumference reduction, improved cardio-metabolic markers, significant liver fat loss in 31 percent of subjects, and reduced urate levels, indicating potential benefits for MASLD resolution and co-morbid conditions like atherosclerosis and renal disease. The drug was well tolerated, with the most common adverse events occurring in ≥5 participants receiving GL0034 were nausea, diarrhoea and vomiting. The study was conducted in Australia.

In the other poster, data from a 10-week safety and efficacy study administering Utreglutide (GL0034) in individuals with obesity was presented. Once-weekly Utreglutide dosing over 10 weeks in individuals with overweight and obesity led to 6.8 percent body weight loss, about 10 percent TC and LDL reduction, 16.3 percent ApoB drop, and significant improvements in inflammatory markers, liver enzymes, and fatty liver index. The study suggested that the drug may show promise for managing cardiovascular risks, with or without type 2 diabetes. The study was conducted in Belgium.

“Obesity and related metabolic conditions continue to challenge the health and well-being of individuals worldwide. At Sun Pharma, we are committed to exploring innovative solutions that can help improve patient outcomes. The early findings with Utreglutide are promising and reinforce our focus on developing therapies that address unmet needs in a meaningful and accessible way,” said Dilip Shanghvi, Chairman, Sun Pharma.

GL0034 was discovered and is being developed by Sun Pharma. Further clinical studies are planned to assess clinical safety and efficacy.

“We observed encouraging reductions in liver fat and improvements across key metabolic parameters with Utreglutide in individuals with obesity and MASLD. In a separate study, the treatment also showed favourable effects on lipid profiles and inflammatory markers in individuals with obesity without diabetes. Utreglutide was well tolerated, and these early findings support continued investigation across broader patient populations,” said Rohit Loomba, Professor of Medicine (with tenure), Chief, Division of Gastroenterology and Hepatology, University of California, San Diego.